

University of Parma Research Repository

Excess weight mediates changes in HDL pool that reduce cholesterol efflux capacity and increase antioxidant activity

This is the peer reviewd version of the followng article:

Original

Excess weight mediates changes in HDL pool that reduce cholesterol efflux capacity and increase antioxidant activity / de Lima-Junior, J. C.; Virginio, V. W. M.; Moura, F. A.; Bertolami, A.; Bertolami, M.; Coelho-Filho, O. R.; Zanotti, I.; Nadruz, W.; de Faria, E. C.; de Carvalho, L. S. F.; Sposito, A. C.. - In: NMCD. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES. - ISSN 0939-4753. - 30:2(2020), pp. 254-264. [10.1016/j.numecd.2019.09.017]

Availability: This version is available at: 11381/2873341 since: 2021-12-20T10:05:21Z

*Publisher:* Elsevier B.V.

Published DOI:10.1016/j.numecd.2019.09.017

Terms of use:

Anyone can freely access the full text of works made available as "Open Access". Works made available

Publisher copyright

note finali coverpage

Elsevier Editorial System(tm) for Nutrition, Metabolism & Cardiovascular Diseases Manuscript Draft

Manuscript Number: NMCD-D-19-00396R1

Title: Excess weight mediates changes in HDL pool that reduce cholesterol efflux capacity and increase antioxidant activity

Article Type: Research Paper

Keywords: atherosclerosis; cholesterol efflux; HDL metabolism; HDL; obesity

Corresponding Author: Professor Andrei C Sposito, MD, PhD

Corresponding Author's Institution: State University of Campinas (UNICAMP)

First Author: Jose C Lima-Junior, MD, PhD

Order of Authors: Jose C Lima-Junior, MD, PhD; Vitor W Virginio, PhD; Filipe A Moura, MD, PhD; Adriana Bertolami, MD, PhD; Marcelo Bertolami, MD, PhD; Otavio R Coelho-Filho, MD, PhD; Ilaria Zanotti, PhD; Wilson Nadruz, MD, PhD; Eliana C Faria, MD, PhD; Luiz S Carvalho, MD, PhD; Andrei C Sposito, MD, PhD

Abstract: Objective: Obesity-related decline in high-density lipoprotein (HDL) functions such as cholesterol efflux capacity (CEC) has supported the notion that this lipoprotein dysfunction may contribute for atherogenesis among obese patients. Besides, potentially other HDL protective actions may be affected with weight gain and these changes may occur even before the obesity range.

Methods: Lipid profile, body mass index (BMI), biochemical measurements, and carotid intima-media thickness (cIMT) were obtained in this cross-sectional study with 899 asymptomatic individuals. HDL functions were measured in a subgroup (n=101).

Results: Individuals with increased HDL-C had an attenuated increase in CIMT with elevation of BMI. CEC, HDL-C, HDL size and HDL-antioxidant activity were negatively associated with cIMT. BMI was inversely associated with HDL-mediated inhibition of platelet aggregation and CEC, but surprisingly it was directly associated with the antioxidant activity. Thus, even in non-obese, non-diabetic individuals, increased BMI is associated with a wide change in protective functions of HDL, reducing CEC and increasing antioxidant activity. In these subjects, decreased HDL concentration, size or function are related to increased atherosclerotic burden.

Conclusion: Our findings demonstrate that in non-obese, non-diabetic individuals, the increasing values of BMI are associated with impaired protective functions of HDL and concomitant increase in atherosclerotic burden.

September the  $2^{nd}$ , 2019,

Dear Editor,

I, along with my coauthors, would like to ask you to reconsider the revised attached manuscript entitled "Excess weight-induced decline of multiple HDL functions favors atherosclerosis" for publication in nutrition metabolism and cardiovascular diseases (NMCD) as a research article.

As required, we answered point-by-point the Reviewers queries (attached) and changed the original text using red fonts to facilitate reading.

We hope the changes have reached the Journal requirements and we look forward to hearing from you in the due course.

Sincerely,

Andrei Sposito, MD, Ph.D

Laboratory of Atherosclerosis and Vascular Biology

Cardiovascular Division - Department of Internal Medicine

Faculty of Medical Sciences - State University of Campinas

Zeferino Vaz Avenue,

Campinas, SP,13084-761

Brazil

TEL: +55 19 35219590

Fax: (19) 35218771

email: andreisposito@gmail.com

#### Ref.: Ms. No.: NMCD-D-19-00396

Jose Carlos de Lima-Junior, Vitor W.M. Virginio, Filipe A. Moura, Adriana Bertolami, Marcelo Bertolami, Otavio R Coelho-Filho, Ilaria Zanotti, Wilson Nadruz, Eliana Cotta de Faria, Luiz Sergio F. de Carvalho, Andrei C Sposito

# Excess weight mediates changes in HDL pool that reduce cholesterol efflux capacity and increase antioxidant activity

Dear Maurizio R. Averna,

I thank you very much for allowing us to resubmit a revised version of our manuscript.

We made all the required modifications and provided the answers point-by-point in order to deal with the questions posed by the Reviewers. We believe the current version of the study is much improved and we hope it reaches the standards for publication in Nutrition, Metabolism & Cardiovascular Diseases.

Prof. Andrei C Sposito Senior Author

Point-by-point answers to Reviewers

Reviewers' comments:

Reviewer #1:

- In this cross-sectional study the Authors assessed the association between body weight, cIMT and HDL levels and in a large cohort of non-diabetic subjects with overweight and no obesity. In a further study performed in a subsample of consecutive patients, they also evaluated the association between BMI and HDL function. In particular, they found a negative association between total cholesterol efflux capacity of HDL and increasing body weight. Both studies are very interesting, innovative and well performed. The only result that is difficult to interpret is the increase in the antioxidant capacity of HDL with increasing BMI. This result is even more surprising as the antioxidant capacity of HDL was negatively correlated with total cholesterol efflux capacity of HDL. In fact, in oveweight and obesity, as well as in the metabolic syndrome, type 2 diabetes and nafld, there is always an increased systemic oxidative stress as the result of increased pro-oxidants and decreased antioxidants such as adiponectin and vitamin E. Therefore, I recommend the authors to better comment on this in the Discussion given the well-known positive relationship between oxidative stress and BMI.

-We agree with the comment and inserted a paragraph expanding this discussion as required (lines 412-421).

Reviewer #2: In this study, the authors aimed to investigate HDL functions in the setting of weight gain. While the topic is of interest, the reviewer has some concerns that are listed below:

1. Table 1, it was mentioned that "All continuous variables are expressed as medians and interquartile ranges". Can you double check the numbers in parentheses and how are these numbers related to interquartile ranges? -We appreciated the issue you raised. We double checked and confirmed these dispersion measurements.

2. How were the subgroup individuals selected? Also, in the full dataset, the age goes higher in high BMI group. In the subgroup, the age difference was not as large. It would be helpful to provide more information about how these people were selected.

-We thank the Reviewer for calling our attention to this lack of clarity and accordingly we included a new statement with details of subgroup selection procedure (lines 126-133).

3. Table 4 is suggested to be rearranged. The current table is hard to follow. It would be easier if the actual linear regression models are provided as well. - As requested, Table 4 has been rearranged to improve its understanding and clarity.

4. Carotid intima-media thickness (cIMT) is a phenotype that is strongly correlated with disease status. Do you have actual disease status in your cohorts? Does it show consistent results?

- We certainly agree with this Reviewer's comment. According to the study design, all enrolled patients were asymptomatic and had a low burden of cardiovascular risk factors. In this way, we have no other aspect of health status to add in the demographics. The follow-up data would certainly inform more about these differences. However, in compliance with national public health standards, since we are a tertiary university hospital, such primary prevention patients must be referred to the primary care network. The question posed by the Reviewer is highly pertinent and we are in the way of raising the follow-up data for such an approach for testing several potential predictors. Unfortunately, raising and adjudicating this data have been time consuming and challenging in many ways, as you certainly know. Thus, although we deeply consider the Reviewer's suggestion, we are not able to obtain this data in timely way for the resubmission of this manuscript.

5. Was CT scans of visceral or subcutaneous fat available? Since BMI is a very general measure of body adiposity and does not differentiate between visceral and subcutaneous fat, it would be very informative to include CT derived fat measures if they are available.

-We completely agree with the suggestion. It would be very informative to have more accurate body composition measurements, but unfortunately, we do not have.

# 6. What are the ethnicities of the individuals? Are they from the same ethnic background? Are they from the same geographic area? Any dietary differences?

- We thank the Reviewer for raising this important question. We have been trying to verify this ethnic interaction in Brazilian population on several occasions and we have been challenged by the limitation of the ethnic definition based on phenotype. In our country, in a recent publication, 20 to 50% of European ancestry was found among black individuals and 1 to 24% of African ancestry was found among phenotypically characterized Caucasians. In the region where the study was conducted, individuals characterized as black have an average of 50% African ancestry and 43% European ancestry (PLoS ONE 6(2): e17063. doi:10.1371/journal.pone.0017063). Despite of this limitation, we included phenotype-based ethnicity of the enrolled individuals and added some comments on the limitation of this approach in the Discussion. Regarding the geographical area, all individuals were enrolled in two cities about 100 km apart. We don't have any information about dietary intake.

7. Since the Antioxidant observation is unexpected. Are there additional individuals available to potentially replication the effect?

- The reviewer is completely right in his/her concern. We were equally surprised by the finding but we believe it is consistent with the change in HDL size that follows weight gain. A large amount of data has demonstrated that smaller particles are usually worse for cholesterol efflux and better in antioxidant activity (J Biol Chem. 2000 Nov 24;275(47):36596-604./ Arterioscler Thromb Vasc Biol. 2004;24:526-533). We insert a paragraph by expanding this discussion and clarifying this hypothesis (lines 369-385). The experiments were repeated to confirm this finding, but always using the same method. To the best of our knowledge, there are no other ways to globally test HDL's antioxidant activity, but rather to test some of HDL's antioxidant proteins mostly PON1. Unfortunately, we did not reserved samples for such additional tests but we agree that a deeper assessment is required to advance the understanding of this matter. We have included this limitation in the Discussion. Reviewer #3: Sposito et al. present a study that explores the potential mechanisms of interaction between HDL functions and overweight on the carotid intima-media thickness of a sample of healthy individuals. Overall the study is well written with a clear hypothesis driven method. The topic is highly important since atherogenesis is not completely understood. However I have some concerns that are described below:

#### <u>Major</u>

When comparing age, LDL-c, total cholesterol, ApoA-I, ApoB and HDL-C between the whole sample and the subsample there is consistent discrepancy across sample described in table 1 and table 2 and table 3 (the last two describing the sample involved in the mechanistic tests and the first describing the study sample). The number of participants described in the abstract, in methods and in the tables are not matching.

-We completely agree and we corrected this lack of clarity stating more clearly that the sample (N=899) analyzed in this paper comes from two separate studies and centers: Dante Pazzanese (339 individuals, NCT02487615) and primary care centers of Campinas (560 individuals, NCT02106013) and that from this sample, a sub-sample with 101 individuals was randomly selected for studying HDL functions.

-Given that some of the main findings of the study are based on a convenience and possibly underpowered sub-sample that may be not representative of study population, I am not sure that the results support the main findings.

- We understand the Reviewer's concern and understand his/her point of view. As we pointed out, functional tests were performed on a subsample due to the fact of being highly laborious methods and, in this study, particularly more laborious due to the original proposal of simultaneously evaluate a set of functional activities of HDL. In most studies, each of these analyzes is done individually, some of them using larger sample size. Reduction in cholesterol efflux capacity, for example, had already been reported in a larger sample of individuals demonstrating that this HDL function decreases in obese individuals; a report consistent with our present finding (Lancet Diabetes Endocrinol 2015; 3: 507–13). The increased antioxidant activity was also recently reported (Lipids Health Dis. 2016 May 11; 15: 92). Such increase in antioxidant activity is consistent with the decrease in HDL size that typically follows weight gain, as reported in the present study and others (J. Lipid Res. 2017. 58: 1916–1923). By these arguments, we believe that the present report deserves to be published and considered by the scientific community, thereby stimulating further replication and deepening in its molecular mechanism.

<u>Minor</u>

-Abstract

The objective is described as a background. The research question should be presented in this section.

-We appreciated the comment and modified as suggested (lines 52-56).

The methods could be described in more details. -We modified as suggested.

<u>Results could present the effect estimates with CI (95%)</u> -We included Spearman's rho value and p values, as well CI 95% and b-value in the abstract.

#### -Methods

The choice of the model is not clear to me. Since insulin is in the pathway of atherogenic dyslipidemia, adjusting for it could potentially "wash" the true association.

-We did a new model for regression analysis without insulin (Table 4) and the effect of the HDL functions in the model looks similar. The individual contribution of "insulin" to the model did not affect the outcome. For instance, in the model with HDL-C, BMI, age, sex, CEC and insulin, the b value of insulin was 0.010 (Std error 0.08, p value 0.229).

#### -Results

Correlation coefficients are presented without prior description in methods section. Additionally, these correlations are interpreted as associations.

-We appreciated that the reviewer noticed this detail. The description of correlation was added in methods section (Lines 244-245) and we made corrections regarding the use of associations when we meant correlation (lines 285 and 303).

| 1        | Ex  | ccess weight mediates changes in HDL pool that reduce cholesterol efflux capacity  |
|----------|-----|--|
| 2        | an  | d increase antioxidant activity  |
| 3        | Jos | se Carlos de Lima-Junior <sup>1</sup> , Vitor W.M. Virginio <sup>1</sup> , Filipe A. Moura <sup>1,2</sup> , Adriana Bertolami <sup>3</sup> , |
| 4        | Ma  | arcelo Bertolami <sup>3</sup> , Otavio R Coelho-Filho <sup>4</sup> , Ilaria Zanotti <sup>6</sup> , Wilson Nadruz <sup>4</sup> , Eliana Cotta |
| 5        | de  | Faria <sup>5</sup> , Luiz Sergio F. de Carvalho <sup>1,4</sup> , Andrei C Sposito <sup>1,4</sup>   |
| 6        | 1.  | Laboratory of Atherosclerosis and Vascular Biology, Faculty of Medical Sciences, State   |
| 7        |     | University of Campinas, São Paulo, Brazil  |
| 8        | 2.  | Department of Cardiology, Brigham and Women's Hospital, Boston, New England,   |
| 9        |     | United States  |
| 10       | 3.  | Department of Dyslipidemia, Dante Pazzanese Cardiological Institute, São Paulo, Brazil   |
| 11       | 4.  | Department of Internal Medicine, Cardiology Division, Faculty of Medical Sciences,   |
| 12       |     | State University of Campinas, São Paulo, Brazil  |
| 13       | 5.  | Lipids Laboratory, Department of Clinical Pathology, Faculty of Medical Sciences,  |
| 14       |     | State University of Campinas, Sao Paulo, Brazil  |
| 15       | 6.  | Department of Food and Drug, University of Parma, Parma, Italy   |
| 16       |     | To whom correspondence should be addressed. E-mail: andreisposito@gmail.com  |
| 17       |     | Corresponding author:  |
| 18       |     | Andrei C Sposito   |
| 19       |     | Cardiology Division, State University of Campinas  |
| 20       |     | 13084-971, Campinas, São Paulo, Brazil   |
| 21       |     | andreisposito@gmail.com  |
| 22       |     | Running title: Excess weight and HDL functions   |
| 23       |     | The authors declare no conflict of interest.   |
| 24       |     | Vermonde sthemestered at the lestered offlow UDL metchelium UDL, sheeiter  |
| 24       |     | <b>Keywords</b> - atheroscierosis; cholesterol efflux; HDL metadolism; HDL; obesity  |
| 25<br>26 |     |  |
| 27       |     |  |

| 28 | Abbreviations: ALT, alanine aminotransferase; ApoA-I, apolipoprotein A-I; AST,                  |
|----|---|
| 29 | aspartate aminotransferase; CE, cholesteryl ester; CEC, Cholesterol efflux capacity; CETP,      |
| 30 | cholesteryl ester transfer protein; cIMT, carotid intima-media thickness; FC, free cholesterol; |
| 31 | HL, hepatic lipase; HOMA2 % $\beta$ , Homeostasis model assessment 2 of beta-cell function;     |
| 32 | HOMA2-IR, Homeostasis model assessment 2 of insulin resistance; HOMA2 %S, Homeostasis           |
| 33 | model assessment 2 of insulin sensitivity; HUVEC, human umbilical vein endothelial cells;       |
| 34 | LCAT, Lecithin-cholesterol acyltransferase activity; PL, phospholipidis; LPL, Lipoprotein       |
| 35 | lipase; PON, paraoxonase; TC, total cholesterol; PLTP, phospholipids transfer protein; VCAM-    |
| 36 | 1, vascular cell adhesion molecule-1.   |
| 37 |   |
| 38 |   |
| 20 |   |
| 39 |   |
| 40 |   |
| 41 |   |
| 42 |   |
| 12 |   |
| 43 |   |
| 44 |   |
| 45 |   |
| 46 |   |
| 47 |   |
| ., |   |
| 48 |   |
| 49 |   |
| 50 |   |

#### **Abstract:**

52 Background: Obesity-related decline in high-density lipoprotein (HDL) functions such 53 as cholesterol efflux capacity (CEC) has supported the notion that this lipoprotein dysfunction 54 may contribute for atherogenesis among obese patients. We investigated if potentially other 55 HDL protective actions may be affected with weight gain and these changes may occur even 56 before the obesity range in a cross-sectional analysis.

57 Methods: Lipid profile, body mass index (BMI), biochemical measurements, and 58 carotid intima-media thickness (cIMT) were obtained in this cross-sectional study with 899 59 asymptomatic individuals. Lipoproteins were separated by ultracentrifugation and HDL 60 physical-chemical characterization, CEC, antioxidant activity, anti-inflammatory activity, HDL-61 mediated platelet aggregation inhibition were measured in a randomly-selected subgroup 62 (n=101).

63 Results: Individuals with increased HDL-C had an attenuated increase in cIMT with elevation of BMI (interaction effect  $\beta$ =-0.054; CI 95% -0.0815, -0.0301). CEC, HDL-C, 64 65 HDL size and HDL-antioxidant activity were negatively associated with cIMT. BMI was 66 inversely correlated with HDL-mediated inhibition of platelet aggregation (Spearman's rho -67 0.157, p < 0.03) and CEC (Spearman's rho -0.32, p<0.001), but surprisingly it was directly 68 correlated with the antioxidant activity (Spearman's rho 0.194, p=0.052). Thus, even in non-69 obese, non-diabetic individuals, increased BMI is associated with a wide change in protective 70 functions of HDL, reducing CEC and increasing antioxidant activity. In these subjects, 71 decreased HDL concentration, size or function are related to increased atherosclerotic burden.

72

Conclusion: Our findings demonstrate that in non-obese, non-diabetic individuals, the 73 increasing values of BMI are associated with impaired protective functions of HDL and 74 concomitant increase in atherosclerotic burden.

- 75
- 76
- 77

#### 1. Introduction

Presently, one in three individuals with excess weight will die from cardiovascular disease (CVD)[1, 2]. In fact, both obesity (BMI >30 kg/m<sup>2</sup>) and overweight (BMI of 25 to <30 kg/m<sup>2</sup>) individuals are at increased risk of cardiovascular death as compared with those with BMI within the normal range (18.5 to <25 kg/m<sup>2</sup>)[3]. The proposed milieu for this interaction involves a spectrum of mechanisms in which phenotypic or functional changes in high-density lipoprotein (HDL) are involved [4].

87 The identification of HDL involvement in adiposopathy is not a recent issue. Since the 88 metabolic syndrome was conceived, all clinical criteria for its diagnosis included low levels of 89 plasma HDL-cholesterol (HDL-C) as a marker of metabolically, unhealthy obesity. In the 90 mechanistic point of view, the combination of increased substrate, such as triglyceride-rich 91 lipoproteins, and increased activity of HDL remodeling proteins, such as cholesteryl ester 92 transfer protein (CETP), and hepatic lipase (HL), coexists in overweight individuals as a result 93 of insulin resistance, promoting a reduction in HDL concentration, size and its content of apolipoproteins AI (ApoA-I). In addition, a decrease in the overall cholesterol efflux capacity 94 95 (CEC) has been reported in obese subjects [5], despite the increased ABCA1-mediated 96 cholesterol efflux[6].

97 Besides CEC, HDL also mediates several other anti-atherosclerotic mechanisms, such 98 as antioxidant, anti-inflammatory activities and inhibition of platelet aggregation, whose extent 99 is sensitive to phenotypic changes of the particles, such as those described above. If this is so, 100 more than the reduced capacity as free cholesterol acceptor, an overall dysfunction in the HDL 101 system may follow weight gain [7]. Furthermore, as the magnitude of these phenotypic changes 102 in HDL occurs in parallel with the increase in BMI, it is possible that a cluster of particle 103 dysfunctions occurs earlier with the weight gain, possibly even before the criterion for 104 overweight. Hence, a metabolic legacy related to HDL may contribute to the future CVD risk. 105 In order to shed some light on these gaps, we designed this study to evaluate the impact of BMI 106 on the interaction between HDL concentration and functions with atherosclerotic burden in pre-107 obese individuals.

#### 108 **2. Materials and methods**

109 **2.1. Cross-sectional study description** 

110 We evaluated a sample of 899 asymptomatic individuals who were invited to participate 111 and were enrolled between 2008 and 2013 in two different studies in two centers about 100 km 112 apart: the outpatient clinic at Dante Pazzanese Institute of Cardiology, São Paulo (SP), Brazil 113 (N=339, NCT02487615) and governmental primary care centers of the city of Campinas, SP, 114 Brazil (N=560, NCT02106013). Inclusion criteria were: (1) no manifested atherosclerotic 115 CVD; (2) no diagnosis of type 2 diabetes based on antidiabetic treatment, fast blood glycemia 116  $\geq$ 126 mg/dL, glycated hemoglobin  $\geq$ 6.5% or glycemia  $\geq$ 200 mg/dL on 120-minutes oral 117 tolerance test and (3) age between 20 and 75 years old. We excluded individuals with (1) 118 uncontrolled hyper (thyroid stimulating hormone (TSH) <0.41µUI/mL or free thyroxin 119 >1.8ng/dL) or hypothyroidism (TSH>4.50µUI/mL or free thyroxin <0.9 ng/dL); (2) antidiabetic 120 medications; (3) liver disease, as indicated by ALT or AST over two times the upper limit; (4) 121 urea >40mg/dL; (5) glomerular filtration rate  $\leq 60$  mL/min/1.73m<sup>2</sup>; (6) heart failure NYHA 122 stage  $\geq$ III; (7) HIV positive or (8) withdrawal of informed consent. Patients underwent clinical 123 examination, as well as biochemical analysis. Subclinical atherosclerosis was measured in all 124 patients up to a month after being included. The study was approved by the local institutional 125 ethical committee of the Dante Pazzanese Institute of Cardiology (registration number 126 3852/2009). It is also registered at ClinicalTrials.Gov by the identification NCT02487615. All 127 patients provided written and informed consent forms before taking part in the study. The study 128 protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki.

The second sample came from the 560 enrolled participants in the governmental primary care centers of the city of Campinas. Initially, we evaluated lipid results from individuals who sought governmental primary care centers (n=598,288). We excluded 544,797 under 40 years of age, LDL> 130 mg / dL and triglycerides> 150mg / dL. From the remaining 133 54,491, we pre-screened by phone 13,381 individuals we were able to contact. We excluded 134 11.845 subjects based on self-reported BMI >30 kg/m<sup>2</sup>, medical treatments, smoking, alcohol 135 use (>14g/day) and individuals engaged in regular physical activity. From the remaining 1.536 136 individuals, 919 attended the clinical visit, we included 560 complete cases based on the 137 inclusion criteria above. Among these, we studied the HDL function of consecutive 101 138 individuals. The study was approved by the local institutional ethical committee of the Hospital 139 das Clínicas of the State University of Campinas (registration number 1260/2010). It is 140 registered at ClinicalTrials.Gov by the identification NCT02106013. All patients provided 141 written and informed consent forms before taking part in the study. The study protocol 142 conforms to the ethical guidelines of the 1975 Declaration of Helsinki.

143 **2.2. Biochemical analysis** 

Blood samples were drawn after a 12-hour fasting period. The following biochemical
measurements were performed: triglycerides, total cholesterol, HDL-C, creatinine, c-reactive
protein (CRP), insulin, glucose, and insulin. LDL-C was calculated using Friedewald's
equation. Glomerular filtration rate was calculated by the CKD-EPI equation. HOMA2 % S,
HOMA2-IR and HOMA2%β were calculated using computer models [8].

149 **2.3. Carotid artery ultrasound** 

150 Carotid Doppler ultrasound was performed using high-resolution Vivid 7 ultrasound 151 (GE, USA) and high-frequency linear transducer (9 MHz) with automatic border recognizer 152 detection as described previously in Bertolami et al [9]. Briefly, the cIMT was obtained by 153 means of image processing of B-mode ultrasonograms of the right and left automatic 154 measurement. High-resolution B-mode ultra-sonographic imaging was performed initially 155 evaluating the common carotid artery with antero-oblique insonation above the clavicle and 156 alongside the internal carotid artery, as standardized procedure[10]. Measurement of cIMT was 157 obtained 20 mm proximally from the carotid bifurcation as the distance between the lumen-158 intima interface and the media-adventitia interface[11].

159 2.4. Lipoprotein isolation

LDL was isolated from a pool of normolipidemic sera from 20 volunteers, through sequential ultracentrifugation using a Beckman L8-M ultracentrifuge (Beckman Coulter Inc., Palo Alto, USA), with a 75Ti fixed angle rotor (Havel, 1955 #11). HDL was isolated from each study participant through density gradient ultracentrifugation[12] with the use of a SW41Ti rotor. Isolated lipoproteins were extensively dialyzed against EDTA-free PBS for 24h, at 4°C, in a dark room. All assays were performed in freshly isolated lipoproteins that were kept at 4°C for a maximum period of 15 days.

167

#### 2.5. HDL chemical composition and molar concentration measurements

168 HDL chemical composition was measured using commercially available enzymatic kits, 169 in the microplate reader Power Wave XS (BioTek®, Winooski, USA). Total proteins (Pierce™ 170 BCA Protein Assay Kit, Thermo Scientific, Rockford, USA), TC (CHOD-PAP, total 171 cholesterol, Roche Diagnostics® reagents, Mannheim, Germany), FC (Free Cholesterol E, 172 Wako Chemicals, Richmond, USA), PL (Phospholipids C, Wako Chemicals, Richmond, USA), 173 TG (TG, GPO-PAP, Roche Diagnostics® reagents, Mannheim, Germany) and ApoA-I (TINA 174 QUANT APOA1 V2, Roche Diagnostics® reagents, Mannheim, Germany) were measured, 175 while CE was calculated according to the following formula: (TC-FC) x 1.67[12]. The relative 176 content of ApoA-I (HDL-ApoA-I) or lipids in HDL was calculated based on their proportion to 177 the total mass of HDL, calculated as the sum of FC, PL, TG, CE, and total proteins. HDL molar 178 concentration was estimated based on particle total mass and molecular weight[12].

179

#### 2.6. HDL physical-chemical characterization

HDL particle size was determined using dynamic light scattering, in a Nanotrac Particle
Size Analyser 250 (Microtrac Inc., Montgomeryville, USA)[13]. Zeta potential was determined
in HDL diluted 1:10 in KCl 10mM, using laser Doppler micro-electrophoresis, in the Zetasizer
Nano ZS (Malvern Instruments, Malvern, UK).

#### 184 2.7. Determination of proteins involved in HDL metabolism

185 CETP and PLTP activities were measured using exogenous radiometric assays, as 186 previously described[14, 15]. LPL and HL activities were measured in fasted post-heparin 187 plasma samples, collected 15min after the intravenous administration of heparin (100U/kg body weight), in an assay based on fatty acid release from a radiolabeled triolein emulsion[16]. LCAT
activity was determined using recombinant HDL, according to standardized method [17]. PON
activity was measured using paraoxon (diethyl-p-nitrophenylphosphate, Sigma, St. Louis, MO,
USA) as substrate [18].

192 **2.8. HDL** antioxidant activity

193 HDL antioxidant activity was measured in a kinetic fluorimetric assay adapted from 194 Navab et al[19]. Oxidation was monitored as changes in the fluorescence intensity of 2',7'-195 dichlorofluoresceine (DCFH). For the antioxidant activity assays, LDL (final concentration, 196 20mgTC/dL) and CuSO<sub>4</sub> (final concentration, 0.5µM) were added to DCFH-containing tubes 197 (final concentration, 2mg/mL), followed by the addition or not of HDL (final concentration, 198 15mg total mass/dL). The volume was adjusted to  $100\mu$ L with Chelex treated-PBS and the 199 reaction mixture transferred onto a black 96-well microplate. The plate was covered with an 200 optical adhesive cover to avoid evaporation and incubated at 37°C. Fluorescence intensity was 201 measured over 24h with 15-minute intervals in a fluorescence microplate reader (Spectra Max 202 M5; Molecular Devices, Sunnyvale, USA) at an excitation wavelength of 485nm, emission 203 wavelength of 540 nm, and cut-off of 530nm. Results of antioxidant activity are presented as the 204 percentage of inhibition of LDL oxidation in the presence of each subject's HDL when 205 compared to control wells (LDL alone).

206

#### 2.9. HDL anti-inflammatory activity

207 HDL's anti-inflammatory activity was measured in HUVEC in an assay adapted from 208 Besler et al[20]. Cells were cultured in RPMI 1640 medium containing 10% fetal calf serum, 209 penicillin, and streptomycin and maintained in a 5% CO<sub>2</sub> incubator at 37°C. After reaching confluence, they were plated in 24-well culture plate  $(3 \times 10^5 \text{ cells/well}, \text{ and incubated with})$ 210 211 TNF- $\alpha$  (1ng/mL), with or without HDL (50µg ApoA-I/mL) for three hours. The culture media 212 were collected and stored at -80°C. Due to the low VCAM-1 concentrations, samples were 213 concentrated using the Amicon® Ultra Centrifugal Filters, 50K (Millipore, Massachusetts, 214 USA) and then VCAM-1 concentrations were measured using the Human VCAM-1 ELISA Kit 215 (Cat number ECM340, Millipore, Massachusetts, USA). Results are expressed as the percentage 216 of decrease in VCAM-1 concentrations in the wells incubated with HDL when compared to the 217 control wells without HDL.

218 **2.10.** Cholesterol efflux capacity (CEC) assay

219 Global cellular CEC was performed using J774 macrophages enriched with acetylated LDL and <sup>14</sup>C-cholesterol and HDL as the cholesterol acceptor[21]. In summary, J774 220 221 macrophages were cultured in RPMI 1640 medium containing 10% fetal calf serum, penicillin, 222 and streptomycin and maintained in a 5% CO<sub>2</sub> incubator at 37°C. After reaching confluence, 223 cells were plated in a 96-well plate  $(1.25 \times 10^5 \text{ cells/well}, \text{ and enriched with acetylated LDL } (50)$ 224  $\mu$ g/mL) and <sup>14</sup>C-free cholesterol (0.3 $\mu$ Ci / mL). After 48h, cells were washed with PBS 225 containing fatty acid-free albumin (FAFA) and equilibrated with DMEM containing FAFA for 226 24 hours. The cells were then washed twice and incubated with HDL (50µg ApoA-I/mL) for 8 227 hours. Media were collected and the radioactivity measured in a beta-scintillation counter. Cells 228 were rinsed twice with cold physiologic saline and the intracellular lipids extracted with hexane: 229 isopropanol (3:2, v/v). Solvent was evaporated and radioactivity measured. The percentage of <sup>14</sup>C-CEC was calculated as (<sup>14</sup>C-cholesterol in the medium/<sup>14</sup>C-cholesterol in cells+medium) 230 231 ×100.

#### 232 2.11. HDL-mediated platelet aggregation inhibition

233 HDL ability to inhibit platelet aggregation was measured as described by Valiyaveettil 234 et al[22]. HDL (0.8mg protein/mL) was mildly oxidized by dialysis against PBS + 5µM CuSO<sub>4</sub>, 235 for 24h at 37°C. Citrated blood was drawn from a healthy donor and platelet-rich plasma (PRP) 236 obtained by centrifugation at 800rpm for 15 minutes. PRP was then incubated with native or 237 oxidized HDL (0.5 mg/mL) for 30 minutes at 37°C. Platelet aggregation was monitored using a 238 Lumi-Aggregometer type 500 VS (Chrono-log, Havertown, USA) for 6 minutes after the 239 addition of ADP (5µM). Results are expressed as percentage of the inhibition of platelet 240 aggregation induced by oxidized compared to native HDL.

#### 241 **2.12. Statistical analysis**

The distribution of all variables was tested with Kolmogorov-Smirnov test. Jonckheere Terpstra trend in one-tail test was used to evaluate demographic, clinical variables and HDL

244 characterization among three groups clustered using BMI and expressed as median and 245 interquartile range. ANCOVA was used to perform comparisons among groups involving 246 enzymatic components of HDL adjusted for age, sex, and HOMA2 %S. Correlations were 247 assessed with the use of nonparametric Spearman coefficients. Mediation analysis using linear models (with a freely available macro for IBM SPSS<sup>®</sup>[23]) were used to assess interactions of 248 249 BMI within the association between HDL functions and cIMT, the only outcome, adjusted for 250 age, sex, HDL-C, BMI, and HOMA2 %S. HDL functions and HDL-C were modeled with 251 generalized linear regression. The BMI effect on the cIMT among six HDL functions (HDL-C, 252 HDL size, antioxidant activity, CEC, HDL-mediated platelet inhibition, and anti-inflammatory 253 activity) was evaluated with the use of interaction tests. We used complete case analysis to 254 handle missing data. To construct the 3D surface plot 1, we included only HDL-C values 255 between 40mg / dL and 100mg / dL; HDL size between 7.0 nm and 9.5 nm; CEC between 8% 256 and 20%; antioxidant activity between 0 and 100%. For the remainder of the regression 257 analyzes, we used the entire sample size of the sub-sample of 99 individuals. Two-sided  $p \le 0.05$ 258 were considered to indicate statistical significance. Analyses were performed using IBM SPSS<sup>®</sup> version 21.0 statistical software. Scatter plot was performed using GraphPad Prism 259 260 version 7.0 for Mac, GraphPad Software, La Jolla California USA, www.graphpad.com". 261 Polinomial splines were used to evaluate the relation between BMI or carotid IMT vs CEC or 262 Antioxidant activity or a compound variable, after transforming CEC and Antioxidant activity 263 into positive z-scores. The compound variable (Z-Efflux + Z-Antioxidant activity) was defined 264 by the sum of z-scores for CEC and antioxidant activity. In order to avoid overfitting, we 265 excluded extreme values at x-axis (<5th percentile and >95% percentile) and smoothing 266 parameters for polinomial derivation (degrees of freedom [df] and lambda) were defined after 267 cross validation. Spline curves were performed in R software, version 3.2.1 (R Foundation for Statistical Computing). We used MATLAB<sup>®</sup> (version 4.10, The MathWorks, Inc, Apple Hill 268 269 Drive Natick, MA) to fit a 3D curve using second polynomial least square surface.

#### **3. Results**

#### 272 3.1. Overall study participants characteristics

The baseline characteristics of participants are shown in Table 1 stratified by BMI status (n=899). Black race prevailed among the participants with increased BMI. Also, the female gender prevailed among the participants and BMI values were associated with waist circumference, increased cIMT and impaired metabolic parameters; *i.e.* lower HDL-C, Apo-AI and HOMA2%S, as well as higher triglycerides, insulin and fasting glucose. Similarly, a stepped increase in LDL-C and total cholesterol was also noted with increasing BMI.

#### 279 3.2. Association between BMI, HDL-C and cIMT

280 In the whole studied sample (n=899), multivariable linear regression analyses adjusted for 281 BMI, age, gender, and plasma insulin or HOMA2-IR, confirmed the association between cIMT 282 and HDL-C ( $\beta$ =-0.11; 95%CI=-0.020;0.000; p=0.03) and identified the existence of a 283 significant interaction of BMI upon this association ( $\beta$ =-0.054; CI 95% -0.0815, -0.0301). To 284 visualize the pattern for such BMI interaction, 3D surface plots were applied based on second 285 polynomial least square regression (Figure 1). As shown in the Figure 1A, in subjects with 286 increased BMI, reduced HDL-C levels were associated with increased cIMT. In contrast, in 287 those individuals with reduced BMI, no clear association was found between HDL-C and cIMT. 288 In order to provide a deeper assessment of this interaction, a broad spectrum of HDL functions 289 was investigated in a subgroup of these individuals. As it would be expected, an inverse 290 correlation was found between BMI and HDL-C (Spearman's rho -0.028, p < 0.0001) and HDL 291

291 size (Spearman's rho -0.175, p < 0.0001).

#### 3.3. Association between BMI, HDL functions and cIMT in the subgroup analyses

The subgroup characteristics are shown on Table 2. In the subgroup, we found a stepped decrease of total HDL mass, HDL size, and HDL content in triglyceride, free cholesterol, cholesteryl ester, and phospholipid across BMI categories (Table 3). PON activity adjusted for the total number of HDL particles, *i.e.* PON/HDL-C ratio, increased in parallel with BMI 297 categories. There was no relation between BMI categories and activities of PLTP, LCAT, HL or298 LPL (Table 3).

299 In line with previous studies, as shown in Figure 2A (linear beta -0.38, polynomial 300 R2=0.19, p=0.001; Spearman's rho -0.32, p<0.001), we reported a progressive decline in CEC 301 as BMI increases. In contrast, we found a progressive increase in HDL antioxidant activity 302 which was proportional and reciprocal as compared with CEC (linear beta +1.38, polynomial 303 R2=0.12, p=0.04; Spearman's rho 0.194, p=0.052) (Figure 2B). Both changes were mainly 304 mediated by the HDL size which is inversely related to weight gain. Based on this assumption, 305 the compound variable of z-transformed efflux plus antioxidant activity should remain 306 approximately constant as HDL size changes due to excess weight (p value 0.75) (Figure 2C). 307 Increasing values of the compound variable were associated lower carotid IMT (linear beta -308 0.10, polynomial R2=0.26, p<0.001) (Figure 2D). Still, correlation analyses were made between 309 BMI and HDL functions. An inverse correlation was also found with HDL-mediated platelet 310 inhibition (Spearman's rho -0.157, p < 0.03). No correlation was found between BMI and HDL 311 anti-inflammatory activity (Spearman's rho -0.009, p < 0.904) nor between each of the HDL 312 functions.

313 Since both the abundance of substrate, *i.e.* triglyceride-rich lipoproteins, and the activities of 314 transport proteins are potentially involved in the effect of excess weight on HDL phenotype, 315 multivariate linear regression models were applied to estimate the influence of intravascular 316 HDL-remodeling proteins, *i.e.* CETP, LPL, HL, LCAT and PLTP on HDL size. CETP ( $\beta$ =-0.12; 317 95%CI=-0.30;-0.01; p=0.030), HL (β=-0.28; 95%CI=-0.35;-0.12; p<0.0001) and LCAT (β=-318 0.36; 95% CI=-0.28;-0.13; p<0.0001) were drivers for HDL size. HDL size was also associated 319 with plasma triglycerides ( $\beta$ =-0.17; 95%CI=-0.06;-0.02; p<0.001), HOMA2-IR ( $\beta$ =0.21; 320 95%CI=0.01;0.42; p=0.001), PON activity/HDL-C (β=-0.33; 95%CI=-0.47;-0.13; p<0.0001) 321 and HDL-mediated antioxidant activity ( $\beta$ =-0.70; 95%CI=-0.81;-0.12; p=0.009). Association 322 was found between HOMA2-IR and HDL-mediated antioxidant activity ( $\beta$ =-2.1; 95%CI=-323 3.66;-0.60; p=0.007).

324 In order to estimate the association between HDL functions and cIMT, we used multiple 325 linear regression with adjustments for the following confounders (BMI, age, sex, HDL-c and 326 insulin), which were selected based on univariate significance or clinical relevance (age, sex) 327 (Table 4). We observed a negative association between CEC and cIMT, which remained 328 significant after initial adjustment for the same confounders above, or even after adjustment for 329 HDL size (β=-0.18; 95%CI=-0.138; -0.011; p=0.02), antioxidant activity (β=-0.19; 95%CI=-330 0.003;0.000; p=0.04) and PON activity/HDL-C (β=-0.16; 95%CI=-0.065;-0.002; p=0.02). The 331 antioxidant activity of HDL was also inversely related to cIMT. Anti-inflammatory activity, 332 PON activity/HDL-C and HDL-mediated platelet inhibition were not associated with cIMT in 333 an adjusted model.

Interactions of BMI were found within the linear associations between cIMT and CEC (p=0.03), and cIMT and antioxidant activity (p=0.04). Although the 95% CI suggests a tendency towards a moderating effect of the BMI on the association between HDL size and cIMT, this interaction did not reach statistical significance (p=0.13) (Fig. 1B). As displayed in Fig 1C, the inverse association between CEC and cIMT seems to increase in parallel with BMI values. In contrast, as shown in Fig 1D, the inverse association between cIMT and antioxidant activity of HDL increases with increasing BMI.

341

343

#### 342 **4. Discussion**

344 Recent data have shown that the predictive value of HDL-C for estimating the risk of 345 cardiovascular events declines after CVD manifestation [24]; a failure that has been attributed to 346 the increased generation of dysfunctional HDL in a setting of chronic or acute disease. As 347 pointed out in subjects with CVD, we hypothesized that excess weight may influence the 348 relationship between HDL-C and the risk of atherosclerotic disease. After confirming this 349 hypothesis, we moved forward investigating whether more subtle changes in the HDL system could occur in overweight individuals and whether this could justify a change in the association 350 351 pattern between HDL-C and atherosclerotic disease. Taken together, our findings revealed the 352 following evidence: (i) the pattern of association between HDL-C and cIMT differs according to the presence or absence of excess weight; (ii) increased BMI is associated with the simultaneous change of multiple anti-atherosclerotic functions of HDL, including CEC and antioxidant activity; (iii) the existing association between excess weight and carotid atherosclerotic burden is in part attributable to HDL dysfunction; and (iv) HDL-mediated inhibition of platelet aggregation declines with excess weight.

To the best of our knowledge, only few studies have previously assessed the impact of body weight on HDL function in non-obese individuals and none used a simultaneous assessment of multiple functions. In this clinical setting, CEC has been the main HDL function assessed, which was investigated in interventional [3], case-control[25] and cross-sectional [5] studies. In a large nested case-control study from the EPIC-Norfolk cohort, for example, discrete changes in BMI in the overweight range was inversely correlated with CEC [25]. On this specific aspect, our results are in line with previous studies.

365 Weight gain promotes a wide range of metabolic changes, among which insulin 366 resistance is the cornerstone for CVD risk. As a result of insulin resistance, for example, there is 367 an increase in the fatty acid efflux and in the activities of CETP and HL leading to a reduction 368 in HDL size, an increase in the ApoA-I catabolic rate and a reduction in CEC[5, 26, 27]. In 369 contrast with the evidence in obese subjects [28-30], our study did not identify changes in CETP 370 and HL activities across BMI categories although their activities were associated with HDL size 371 change. Thus, at this stage of excess weight, the biochemical and size changes in HDL particles 372 is more likely a consequence of increased substrate for HDL particle remodeling, *i.e.* increased 373 plasma concentration of triglyceride-rich lipoproteins.

These changes in the HDL system have traditionally been reported as a component cause for the increased risk of CVD in obese individuals[31]. In those who are overweight but below the obesity threshold, we revealed a similar scenario, *i.e.* insulin resistance inversely relates with overweight, HDL size and CEC. It is interesting to note that these changes occurred even before the threshold for overweight as defined by World Health Organization (WHO). Thus, according to previous translational studies[32] or actuarial analyzes based on observational cohorts[33], our data support the concept that the threshold for pathogenic bodymass is probably below the WHO definition.

382 Although it is clear that there is functional impairment, it is plausible that the change in 383 the HDL phenotype would have an adaptive biological purpose motivated by the chronic 384 increase of oxidative stress and by low-grade systemic inflammation triggered by weight gain. 385 Such adaptive response has been reported in distinct scenarios related to excess weight, in 386 accumulation of brown adipose tissue (BAT). BAT from obese mice have increased reactive 387 oxygen species (ROS) generation that is followed by a concomitant increase in antioxidant 388 enzymes catalase (CAT), superoxide dismutase (SOD) and glutathione peroxidase [34, 35]. In 389 this way, we believe that in individuals with low burden of cardiovascular risk factors such as 390 those enrolled in this study, a decrease in HDL size may represent an adaptive strategy to 391 attenuate the increased oxidative stress. Whether the onset of obesity complications such as 392 diabetes or hypertension may or may not affect this adaptive response we do not currently 393 know. Further studies are needed to verify this hypothesis.

394 Evidence from clinical studies suggest that HDL antioxidant capacity is proportionally 395 increased in individuals with high blood levels of serum amyloid A (SAA) levels, which usually 396 occur in acute stress situations [36]. In addition, plasma proteome remodeling with weight loss is 397 accompanied by decrease in SAA[37], although it is not possible to extrapolate to the rational 398 weight gain/increased SAA/increased HDL antioxidant capacity. Conversely, a recent paper 399 [38] demonstrated that there is a non-significant trend towards an increase in total HDL 400 antioxidant activity (780 vs 620 nmol / ml sample) in obese white individuals (mean BMI 33.4 401  $\pm$  0.8) versus normal-weight individuals (mean BMI 22.6  $\pm$  0.7). This trend is inverse (640 vs 402 800 nmol / ml sample) in obese black individuals (mean BMI 38.5  $\pm$  0.7) versus normal-weight 403 black individuals (BMI 22.8  $\pm$  0.9), although there is a significant BMI difference between the 404 obese groups before we conclude that it is only an impact of ethnicity.

Similar reduction of HDL size has been reported in individuals who exhibit acute phase
response, such as in myocardial infarction[39] and sepsis[40]. In these conditions, the reduction
of HDL size is associated with a greater capacity to mitigate the oxidative stress. In agreement

408 with this and consistent with previous studies, HDL size was inversely associated with 409 increased antioxidant and PON activities[41]. Interestingly, the predominance of small HDL 410 (7.3-8.2 nm) in this cohort was associated with an attenuated impact of BMI on cIMT. Hence, 411 overweight-induced remodeling in HDL simultaneously promoted the reduction of an anti-412 atherosclerotic mechanism, i.e. CEC, and the increase of another, i.e. antioxidant activity, 413 suggesting a biological response of the HDL system to the predominant pro-atherosclerotic 414 stimulus [42, 43]. Besides, the present study shows that estimates of the magnitude of HDL 415 participation in the CVD risk in excess weight are naturally imprecise unless a broad range of 416 anti-atherosclerotic functions is simultaneously investigated.

417 Obesity is clearly shown to be a prothrombotic state resulting from a combination of 418 increased thrombin generation, platelet hyperactivity and decreased fibrinolysis[44]. Increased 419 platelet reactivity is the result of the interaction between multiple characteristics grouped into 420 obesity, including inflammation, oxidative stress, insulin resistance and adiposopathy with 421 change in adipokine secretion pattern. Our study added to this state of knowledge, a new 422 mechanism of imbalance in platelet activity; inhibition of HDL-mediated platelet aggregation 423 was inversely associated with BMI. This finding should be considered in the set of 424 prothrombotic changes of excess weight and as one of the mechanisms by which there is an 425 increase in the incidence of cardiovascular events in these individuals.

426 Among the main limitations in the present study lies the fact that it is based on a cross-427 sectional design. In addition, due to the intensive laborious methodology involved in studying a 428 full breadth of HDL function and metabolic pathways, we may have not been able to maintain 429 the desired statistical power obtained as when the entire studied population was analyzed. In 430 spite of this, it does provide us a unique opportunity to evaluate the association between excess 431 weight and the HDL system early in the spectrum of metabolic derangement and atherogenesis. 432 In fact, this may especially be true given the low rates of insulin resistance and more favorable 433 lipid profile and systemic inflammatory activity of our study's participants. We found small 434 differences in ethnicity, particularly for those with excess weight, that may potentially influence 435 the metabolic status. However, in the region where the study was conducted, individuals

436 characterized as black have an average of 50% African ancestry and 43% European ancestry, 437 which may limit of ability to interpret this finding[45]. To the best of our knowledge, the global 438 antioxidant activity evaluated in this study is best approach available. Nevertheless, this assay 439 does not provide information about HDL's specific antioxidant proteins activity such as 440 paraoxonase-1, glutathione peroxidase and phospholipase A2. This finding requires a further 441 assessment in greater detail.

In conclusion, our study indicates that higher BMI, even in non-obese, non-diabetic individuals, is associated with decreased function of several protective activities of HDL. In individuals with increased BMI, HDL dysfunction is directly associated with increased atherosclerotic burden. Antioxidant activity is found to be an exception increasing with BMI and it partially attenuated the atherosclerotic burden. 447 **Declaration of interest**: The authors declare no conflict of interest.

Funding The study was supported by São Paulo Research Foundation (FAPESP 2010/00201-8 and FAPESP 2006/60585-9 and CNPq (471380/2008-13). JCLJ was supported by a doctoral grant from Coordination for the Improvement of Higher-Level Education Personnel (Capes grant number PROEX0092045). NBP was supported by a doctoral grant (number 2012/01645-2) from the Foundation for Research Support of the State of Sao Paulo (FAPESP). Prof Sposito was supported by a fellowship grant of productivity in research from the National Council for Scientific and Technological Development (CNPq) (grant number 301465/2017-7).

455 Author contribution statement: Jose Carlos de Lima-Junior drafted the manuscript and 456 participated on the analysis of the data, Vitor W.M. Virginio participated on the experiments, 457 Filipe A. Moura participated on the drafting of the manuscript and analysis of the data, Adriana 458 Bertolami participated on the experiments, Marcelo Bertolami participated critically reviewing 459 the manuscript, Wilson Nadruz participated critically reviewing the manuscript, Eliana Cota de 460 Faria participated on the experiments and analysis of the data, Ilaria Zanotti participated 461 critically reviewing the manuscript, Luiz Sergio F. de Carvalho participated on the analysis of 462 the data and critically reviewing the manuscript, Andrei C Sposito participated on the analysis 463 of the data and critically reviewing the manuscript

464 Acknowledgements. We thank Natalia B. Panzoldo from the University of Campinas for465 technical assistance in HDL functions experiments.

466

[1] D.K. Tobias, A. Pan, C.L. Jackson, E.J. O'Reilly, E.L. Ding, W.C. Willett, J.E. Manson, F.B. Hu,
Body-mass index and mortality among adults with incident type 2 diabetes, N Engl J Med
370(3) (2014) 233-44.

- 472 [2] A. Afshin, M.H. Forouzanfar, M.B. Reitsma, P. Sur, K. Estep, A. Lee, L. Marczak, A.H.
- 473 Mokdad, M. Moradi-Lakeh, M. Naghavi, J.S. Salama, T. Vos, K.H. Abate, C. Abbafati, M.B.
- 474 Ahmed, Z. Al-Aly, A. Alkerwi, R. Al-Raddadi, A.T. Amare, A. Amberbir, A.K. Amegah, E. Amini,
- 475 S.M. Amrock, R.M. Anjana, J. Ärnlöv, H. Asayesh, A. Banerjee, A. Barac, E. Baye, D.A. Bennett,
- 476 A.S. Beyene, S. Biadgilign, S. Biryukov, E. Bjertness, D.J. Boneya, I. Campos-Nonato, J.J. Carrero,
- 477 P. Cecilio, K. Cercy, L.G. Ciobanu, L. Cornaby, S.A. Damtew, L. Dandona, R. Dandona, S.D.
- 478 Dharmaratne, B.B. Duncan, B. Eshrati, A. Esteghamati, V.L. Feigin, J.C. Fernandes, T. Fürst, T.T.
- 479 Gebrehiwot, A. Gold, P.N. Gona, A. Goto, T.D. Habtewold, K.T. Hadush, N. Hafezi-Nejad, S.I.
- 480 Hay, M. Horino, F. Islami, R. Kamal, A. Kasaeian, S.V. Katikireddi, A.P. Kengne, C.N.
- 481 Kesavachandran, Y.S. Khader, Y.H. Khang, J. Khubchandani, D. Kim, Y.J. Kim, Y. Kinfu, S. Kosen,
- 482 T. Ku, B.K. Defo, G.A. Kumar, H.J. Larson, M. Leinsalu, X. Liang, S.S. Lim, P. Liu, A.D. Lopez, R.
- 483 Lozano, A. Majeed, R. Malekzadeh, D.C. Malta, M. Mazidi, C. McAlinden, S.T. McGarvey, D.T.
- 484 Mengistu, G.A. Mensah, G.B.M. Mensink, H.B. Mezgebe, E.M. Mirrakhimov, U.O. Mueller, J.J.
- 485 Noubiap, C.M. Obermeyer, F.A. Ogbo, M.O. Owolabi, G.C. Patton, F. Pourmalek, M. Qorbani, A.
- 486 Rafay, R.K. Rai, C.L. Ranabhat, N. Reinig, S. Safiri, J.A. Salomon, J.R. Sanabria, I.S. Santos, B.
- 487 Sartorius, M. Sawhney, J. Schmidhuber, A.E. Schutte, M.I. Schmidt, S.G. Sepanlou, M.
  488 Shamsizadeh, S. Sheikhbahaei, M.J. Shin, R. Shiri, I. Shiue, H.S. Roba, D.A.S. Silva, J.I. Silverbe
- Shamsizadeh, S. Sheikhbahaei, M.J. Shin, R. Shiri, I. Shiue, H.S. Roba, D.A.S. Silva, J.I. Silverberg,
  J.A. Singh, S. Stranges, S. Swaminathan, R. Tabarés-Seisdedos, F. Tadese, B.A. Tedla, B.S.
- J.A. Singh, S. Stranges, S. Swaminathan, R. Tabarés-Seisdedos, F. Tadese, B.A. Tedla, B.S.
   Tegegne, A.S. Terkawi, J.S. Thakur, M. Tonelli, R. Topor-Madry, S. Tyrovolas, K.N. Ukwaja, O.A.
- Tegegne, A.S. Terkawi, J.S. Thakur, M. Tonelli, R. Topor-Madry, S. Tyrovolas, K.N. Ukwaja, O.A.
  Uthman, M. Vaezghasemi, T. Vasankari, V.V. Vlassov, S.E. Vollset, E. Weiderpass, A. Werdecker,
- 492 J. Wesana, R. Westerman, Y. Yano, N. Yonemoto, G. Yonga, Z. Zaidi, Z.M. Zenebe, B. Zipkin,
- 493 C.J.L. Murray, G.O. Collaborators, Health Effects of Overweight and Obesity in 195 Countries
- 494 over 25 Years, N Engl J Med 377(1) (2017) 13-27.
- 495 [3] A.A. Khan, P.A. Mundra, N.E. Straznicky, P.J. Nestel, G. Wong, R. Tan, K. Huynh, T.W. Ng,
- 496 N.A. Mellett, J.M. Weir, C.K. Barlow, Z.H. Alshehry, G.W. Lambert, B.A. Kingwell, P.J. Meikle,
- 497 Weight Loss and Exercise Alter the High-Density Lipoprotein Lipidome and Improve High-
- 498 Density Lipoprotein Functionality in Metabolic Syndrome, Arterioscler Thromb Vasc Biol 38(2)499 (2018) 438-447.
- 500 [4] F.M. Sacks, M.K. Jensen, From High-Density Lipoprotein Cholesterol to Measurements of501 Function: Prospects for the Development of Tests for High-Density Lipoprotein Functionality in
- 502 Cardiovascular Disease, Arterioscler Thromb Vasc Biol 38(3) (2018) 487-499.
- 503 [5] T. Sasahara, P. Nestel, N. Fidge, D. Sviridov, Cholesterol transport between cells and high
- 504 density lipoprotein subfractions from obese and lean subjects, J Lipid Res 39(3) (1998) 544-54.
- 505 [6] N. Attia, N. Fournier, B. Vedie, M. Cambillau, P. Beaune, O. Ziegler, A. Grynberg, J.L. Paul, B.
- 506 Guerci, Impact of android overweight or obesity and insulin resistance on basal and
- 507 postprandial SR-BI and ABCA1-mediated serum cholesterol efflux capacities, Atherosclerosis 508 209(2) (2010) 422-9.
- 509 [7] A.C. Sposito, HDL metrics, let's call the number thing off?, Atherosclerosis 251 (2016) 525-510 527.
- 511 [8] J.C. Levy, D.R. Matthews, M.P. Hermans, Correct homeostasis model assessment (HOMA)
- 512 evaluation uses the computer program, Diabetes Care 21(12) (1998) 2191-2.
- 513 [9] A. Bertolami, J.C. de Lima-Júnior, R.M. Cintra, L.S. Carvalho, C.C. Gonzaga, M.L. Sulzbach,
- 514 A.C.G.P. Petisco, J.E.M. Barbosa, A.A. Faludi, J. Plutzky, M.C. Bertolami, A.C. Sposito,
- Adiponectin concentration data improve the estimation of atherosclerotic risk in normal and in
- 516 overweight subjects, Clin Endocrinol (Oxf) (2017).

- 517 [10] J.H. Stein, C.E. Korcarz, R.T. Hurst, E. Lonn, C.B. Kendall, E.R. Mohler, S.S. Najjar, C.M.
- 518 Rembold, W.S. Post, F. American Society of Echocardiography Carotid Intima-Media Thickness
- 519 Task, Use of carotid ultrasound to identify subclinical vascular disease and evaluate
- 520 cardiovascular disease risk: a consensus statement from the American Society of
- 521 Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for
- 522 Vascular Medicine, Journal of the American Society of Echocardiography : official publication of 523 the American Society of Echocardiography 21(2) (2008) 93-111; quiz 189-90.
- 524 [11] M.W. Lorenz, S. von Kegler, H. Steinmetz, H.S. Markus, M. Sitzer, Carotid intima-media
- 525 thickening indicates a higher vascular risk across a wide age range: prospective data from the
- 526 Carotid Atherosclerosis Progression Study (CAPS), Stroke 37(1) (2006) 87-92.
- 527 [12] M.J. Chapman, S. Goldstein, D. Lagrange, P.M. Laplaud, A density gradient ultracentrifugal
- procedure for the isolation of the major lipoprotein classes from human serum, J Lipid Res22(2) (1981) 339-58.
- 530 [13] E.S. Lima, R.C. Maranhao, Rapid, simple laser-light-scattering method for HDL particle531 sizing in whole plasma, Clin Chem 50(6) (2004) 1086-8.
- 532 [14] L. Lagrost, Determination of the mass concentration and the activity of the plasma
- 533 cholesteryl ester transfer protein (CETP), Methods Mol Biol 110 (1998) 231-41.
- [15] M. Jauhiainen, C. Ehnholm, Determination of human plasma phospholipid transfer protein
   mass and activity, Methods 36(2) (2005) 97-101.
- 536 [16] C. Ehnholm, T. Kuusi, Preparation, characterization, and measurement of hepatic lipase, 537 Methods Enzymol 129 (1986) 716-38.
- 538 [17] J.W. Chisholm, A.K. Gebre, J.S. Parks, Characterization of C-terminal histidine-tagged
- 539 human recombinant lecithin:cholesterol acyltransferase, J Lipid Res 40(8) (1999) 1512-9.
- 540 [18] D.Z. Scherrer, V.H. Zago, I.C. Vieira, E.S. Parra, N.B. Panzoldo, F. Alexandre, R. Secolin, J.
- 541 Baracat, E.C. Quintão, E.C. Faria, p.Q192R SNP of PON1 seems not to be Associated with
- 542 Carotid Atherosclerosis Risk Factors in an Asymptomatic and Normolipidemic Brazilian 543 Population Sample, Arg Bras Cardiol 105(1) (2015) 45-52.
- 544 [19] M. Navab, S.Y. Hama, G.P. Hough, G. Subbanagounder, S.T. Reddy, A.M. Fogelman, A cell-545 free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating 546 oxidized phospholipids, J Lipid Res 42(8) (2001) 1308-17.
- 547 [20] C. Besler, K. Heinrich, L. Rohrer, C. Doerries, M. Riwanto, D.M. Shih, A. Chroni, K.
- 548 Yonekawa, S. Stein, N. Schaefer, M. Mueller, A. Akhmedov, G. Daniil, C. Manes, C. Templin, C.
- 549 Wyss, W. Maier, F.C. Tanner, C.M. Matter, R. Corti, C. Furlong, A.J. Lusis, A. von Eckardstein,
- 550 A.M. Fogelman, T.F. Luscher, U. Landmesser, Mechanisms underlying adverse effects of HDL
- on eNOS-activating pathways in patients with coronary artery disease, J Clin Invest 121(7)
   (2011) 2693-708.
- 553 [21] A. Machado-Lima, R.T. Iborra, R.S. Pinto, C.H. Sartori, E.R. Oliveira, E.R. Nakandakare, J.T.
- 554 Stefano, D. Giannella-Neto, M.L. Correa-Giannella, M. Passarelli, Advanced glycated albumin
- isolated from poorly controlled type 1 diabetes mellitus patients alters macrophage gene
- expression impairing ABCA-1-mediated reverse cholesterol transport, Diabetes Metab Res Rev
   29(1) (2013) 66-76.
- 558 [22] M. Valiyaveettil, N. Kar, M.Z. Ashraf, T.V. Byzova, M. Febbraio, E.A. Podrez, Oxidized high-
- density lipoprotein inhibits platelet activation and aggregation via scavenger receptor BI, Blood111(4) (2008) 1962-71.
- 561 [23] K.J. Preacher, A.F. Hayes, SPSS and SAS procedures for estimating indirect effects in simple 562 mediation models, Behav Res Methods Instrum Comput 36(4) (2004) 717-31.
- 563 [24] G. Silbernagel, B. Schottker, S. Appelbaum, H. Scharnagl, M.E. Kleber, T.B. Grammer, A.
- 564 Ritsch, U. Mons, B. Holleczek, G. Goliasch, A. Niessner, B.O. Boehm, R.B. Schnabel, H. Brenner,
- 565 S. Blankenberg, U. Landmesser, W. Marz, High-density lipoprotein cholesterol, coronary artery 566 disease, and cardiovascular mortality, Eur Heart J 34(46) (2013) 3563-71.
- 567 [25] D. Saleheen, R. Scott, S. Javad, W. Zhao, A. Rodrigues, A. Picataggi, D. Lukmanova, M.L.
- 568 Mucksavage, R. Luben, J. Billheimer, J.J. Kastelein, S.M. Boekholdt, K.T. Khaw, N. Wareham, D.J.

- 569 Rader, Association of HDL cholesterol efflux capacity with incident coronary heart disease
- 570 events: a prospective case-control study, Lancet Diabetes Endocrinol 3(7) (2015) 507-13.
- 571 [26] E.S. Parra, N.B. Panzoldo, V.H. Zago, D.Z. Scherrer, F. Alexandre, J. Bakkarat, V.S. Nunes,
- 572 E.R. Nakandakare, E.C. Quintao, W. Nadruz, Jr., E.C. de Faria, A.C. Sposito, HDL size is more
- 573 accurate than HDL cholesterol to predict carotid subclinical atherosclerosis in individuals 574 classified as low cardiovascular risk, PLoS One 9(12) (2014) e114212.
- 575 [27] M. de la Llera Moya, F.C. McGillicuddy, C.C. Hinkle, M. Byrne, M.R. Joshi, V. Nguyen, J.
- 576 Tabita-Martinez, M.L. Wolfe, K. Badellino, L. Pruscino, N.N. Mehta, B.F. Asztalos, M.P. Reilly,
- 577 Inflammation modulates human HDL composition and function in vivo, Atherosclerosis 222(2) 578 (2012) 390-4.
- 579 [28] T. Arai, S. Yamashita, K. Hirano, N. Sakai, K. Kotani, S. Fujioka, S. Nozaki, Y. Keno, M.
- 580 Yamane, E. Shinohara, Increased plasma cholesteryl ester transfer protein in obese subjects. A 581 possible mechanism for the reduction of serum HDL cholesterol levels in obesity, Arterioscler 582 Thromb 14(7) (1994) 1129-36.
- 583 [29] C.F. Ebenbichler, M. Laimer, S. Kaser, A. Ritsch, A. Sandhofer, H. Weiss, F. Aigner, J.R.
- 584 Patsch, Relationship between cholesteryl ester transfer protein and atherogenic lipoprotein
- 585 profile in morbidly obese women, Arterioscler Thromb Vasc Biol 22(9) (2002) 1465-9.
- 586 [30] C.P.J. Talbot, J. Plat, P.J. Joris, M. Konings, Y.H.A.M. Kusters, C.G. Schalkwijk, A. Ritsch, R.P.
- 587 Mensink, HDL cholesterol efflux capacity and cholesteryl ester transfer are associated with 588 body mass, but are not changed by diet-induced weight loss: A randomized trial in abdominally 589
- obese men, Atherosclerosis 274 (2018) 23-28.
- 590 [31] B. Shao, C. Tang, A. Sinha, P.S. Mayer, G.D. Davenport, N. Brot, M.N. Oda, X.Q. Zhao, J.W. 591 Heinecke, Humans with atherosclerosis have impaired ABCA1 cholesterol efflux and enhanced
- 592 high-density lipoprotein oxidation by myeloperoxidase, Circ Res 114(11) (2014) 1733-42.
- 593 [32] L.H. Bogl, S.M. Kaye, J.T. Ramo, A.J. Kangas, P. Soininen, A. Hakkarainen, J. Lundbom, N.
- 594 Lundbom, A. Ortega-Alonso, A. Rissanen, M. Ala-Korpela, J. Kaprio, K.H. Pietilainen, Abdominal
- 595 obesity and circulating metabolites: A twin study approach, Metabolism 65(3) (2016) 111-21.
- 596 [33] K. Bhaskaran, I. Dos-Santos-Silva, D.A. Leon, I.J. Douglas, L. Smeeth, Association of BMI
- 597 with overall and cause-specific mortality: a population-based cohort study of 3.6 million adults 598 in the UK, Lancet Diabetes Endocrinol (2018).
- 599 [34] M. Alcalá, M. Calderon-Dominguez, E. Bustos, P. Ramos, N. Casals, D. Serra, M. Viana, L.
- 600 Herrero, Increased inflammation, oxidative stress and mitochondrial respiration in brown 601 adipose tissue from obese mice, Sci Rep 7(1) (2017) 16082.
- 602 [35] K. Mahdaviani, I.Y. Benador, S. Su, R.A. Gharakhanian, L. Stiles, K.M. Trudeau, M.
- 603 Cardamone, V. Enríquez-Zarralanga, E. Ritou, T. Aprahamian, M.F. Oliveira, B.E. Corkey, V.
- 604 Perissi, M. Liesa, O.S. Shirihai, Mfn2 deletion in brown adipose tissue protects from insulin
- 605 resistance and impairs thermogenesis, EMBO Rep 18(7) (2017) 1123-1138.
- 606 [36] B.F. Asztalos, K.V. Horvath, M. Mehan, Y. Yokota, E.J. Schaefer, Influence of HDL particles
- 607 on cell-cholesterol efflux under various pathological conditions, J Lipid Res 58(6) (2017) 1238-608 1246.
- 609 [37] P.E. Geyer, N.J. Wewer Albrechtsen, S. Tyanova, N. Grassl, E.W. lepsen, J. Lundgren, S.
- 610 Madsbad, J.J. Holst, S.S. Torekov, M. Mann, Proteomics reveals the effects of sustained weight
- 611 loss on the human plasma proteome, Mol Syst Biol 12(12) (2016) 901.
- 612 [38] N.J. Woudberg, J.H. Goedecke, D. Blackhurst, M. Frias, R. James, L.H. Opie, S. Lecour,
- 613 Association between ethnicity and obesity with high-density lipoprotein (HDL) function and 614 subclass distribution, Lipids Health Dis 15 (2016) 92.
- 615 [39] L.S. Carvalho, V.W. Virginio, N.B. Panzoldo, V.N. Figueiredo, S.N. Santos, R.G. Modolo, J.M.
- 616 Andrade, E.S.J.C. Quinaglia, W. Nadruz-Junior, E.C. de Faria, A.C. Sposito, G. Brasilia Heart
- 617 Study, Elevated CETP activity during acute phase of myocardial infarction is independently
- 618 associated with endothelial dysfunction and adverse clinical outcome, Atherosclerosis 237(2)
- 619 (2014) 777-83.

- 620 [40] A. Pirillo, A.L. Catapano, G.D. Norata, HDL in infectious diseases and sepsis, Handb Exp 621 Pharmacol 224 (2015) 483-508.
- 622 [41] A. Kontush, S. Chantepie, M.J. Chapman, Small, dense HDL particles exert potent
- protection of atherogenic LDL against oxidative stress, Arterioscler Thromb Vasc Biol 23(10)(2003) 1881-8.
- 625 [42] A. Kontush, E.C. de Faria, S. Chantepie, M.J. Chapman, Antioxidative activity of HDL
- 626 particle subspecies is impaired in hyperalphalipoproteinemia: relevance of enzymatic and 627 physicochemical properties, Arterioscler Thromb Vasc Biol 24(3) (2004) 526-33.
- 628 [43] P.G. Yancey, M. de la Llera-Moya, S. Swarnakar, P. Monzo, S.M. Klein, M.A. Connelly, W.J.
- 629 Johnson, D.L. Williams, G.H. Rothblat, High density lipoprotein phospholipid composition is a
- 630 major determinant of the bi-directional flux and net movement of cellular free cholesterol
- 631 mediated by scavenger receptor BI, J Biol Chem 275(47) (2000) 36596-604.
- 632 [44] F. Santilli, N. Vazzana, R. Liani, M.T. Guagnano, G. Davi, Platelet activation in obesity and 633 metabolic syndrome, Obes Rev 13(1) (2012) 27-42.
- 634 [45] S.D. Pena, G. Di Pietro, M. Fuchshuber-Moraes, J.P. Genro, M.H. Hutz, S. Kehdy Fde, F.
- Kohlrausch, L.A. Magno, R.C. Montenegro, M.O. Moraes, M.E. de Moraes, M.R. de Moraes, E.B.
- 636 Ojopi, J.A. Perini, C. Racciopi, A.K. Ribeiro-Dos-Santos, F. Rios-Santos, M.A. Romano-Silva, V.A.
- 637 Sortica, G. Suarez-Kurtz, The genomic ancestry of individuals from different geographical
- 638 regions of Brazil is more uniform than expected, PLoS One 6(2) (2011) e17063.

Figure 1. 3D surface plot showing the association between BMI, cIMT, and HDL variables. This surface plot displays an image based on the relationship between the BMI and HDL variables as predictors on the x- and y-axes and a continuous surface that represents the cIMT values on the z-axis. The peak on the plot corresponds with the yellow color and the highest value obtained to cIMT using the combination of X and Y that produce the maxima cIMT, which occurs at approximately 0.8mm. The valley corresponds with blue color and the combination of X and Y that produce the minima cIMT. Figure 1A, HDL-C values. Figure 1B, HDL size. Figure 1C, CEC values. Figure 1D, antioxidant activity of HDL. HDL-C, high-density lipoprotein cholesterol in mg/dL. BMI, body mass index in kg/m<sup>2</sup>. CEC is expressed as a percentage of efflux in the sample, normalized to a reference sample. Antioxidant activity is expressed in % as inhibition of LDL oxidation in the presence of each subject's HDL oxidation. Figure 2. Polynomial splines showing the associations between BMI, cIMT and HDL variables. 2A, CEC according to BMI values. 2B, Antioxidant activity according to BMI values. 2C, compound variable (Z-Efflux + Z-Antioxidant activity) according to BMI values. 2D, cIMT values according to compound variable (Z-Efflux + Z-Antioxidant activity). Gray shading indicates 95% confidence intervals. 

| 669 | Table 1. | Clinical | characteristics | according to | BMI | groups |
|-----|----------|----------|-----------------|--------------|-----|--------|
|-----|----------|----------|-----------------|--------------|-----|--------|

|                          | <22           | 22-24.99                | >25 <i>p</i> -             | value    |  |
|--------------------------|---------------|-------------------------|----------------------------|----------|--|
| Sample size              | 186           | 264                     | 449                        |          |  |
| Black race, %            | 4.0           | 6.7                     | 15.2                       | 0.029    |  |
| BMI, kg/m <sup>2</sup>   | 20.6 (1.8)    | 23.6 (1.6) <sup>a</sup> | 28 (4.6) <sup>b,c</sup>    | <0.0001  |  |
| Waist circumference, cm  | 68 (9)        | 75 (11) <sup>a</sup>    | 94 (19) <sup>b,c</sup>     | <0.0001  |  |
| Age, yr                  | 38 (24)       | 45.5 (26) <sup>a</sup>  | 54 (16) <sup>b</sup>       | 0.003    |  |
| Male sex, %              | 43.5          | 44.7                    | 39.6                       | 0.369    |  |
| Hypertension, %          | 28.6          | 31.3                    | 28.3                       | 0.915    |  |
| Glucose, mg/dL           | 81 (12)       | 86 (14) <sup>a</sup>    | 105 (62) <sup>b,c</sup>    | < 0.0001 |  |
| Insulin, μU/mL           | 3.0 (2.5)     | 4.7 (4.9) <sup>a</sup>  | 10.2 (8.2) <sup>b,c</sup>  | <0.0001  |  |
| HOMA2 % β                | 61.9 (38.2)   | 61.3 (49.4)             | 64.9 (51.3) <sup>b,c</sup> | 0.008    |  |
| HOMA2 %S                 | 241.7 (210.3) | 161.2 (183.5)           | 68.8 (62.5) <sup>b,c</sup> | <0.0001  |  |
| HOMA2-IR                 | 0.46 (0.4)    | 0.51 (0.5)              | $0.66 (0.5)^{b,c}$         | < 0.0001 |  |
| CRP, mg/dL               | 0.42 (0.9)    | 0.70 (1.1)              | 0.51 (1.0)                 | 0.453    |  |
| Triglycerides, mg/dL     | 66 (34)       | 81 (46) <sup>a</sup>    | 118 (87) <sup>b,c</sup>    | <0.0001  |  |
| LDL-C, mg/dL             | 95 (40)       | 104 (34) <sup>a</sup>   | 107 (42) <sup>b</sup>      | <0.0001  |  |
| Total cholesterol, mg/dL | 175 (53)      | 181 (50)                | 187 (55) <sup>b,c</sup>    | < 0.0001 |  |
| ApoA-I, mg/dL            | 148 (53)      | 142 (46)                | 137 (38) <sup>b,c</sup>    | <0.0001  |  |
| ApoB, mg/dL              | 72 (23)       | 81 (27) <sup>a</sup>    | 90 (31) <sup>b</sup>       | < 0.0001 |  |

| HDL-C, mg/dL | 63 (29)     | 52 (30) <sup>a</sup>     | $45(19)^{b,c}$             | <0.0001  |
|--------------|-------------|--------------------------|----------------------------|----------|
| cIMT, mm     | 0.55 (0.20) | 0.60 (0.20) <sup>a</sup> | 0.70 (0.24) <sup>b,c</sup> | < 0.0001 |

All continuous variables are expressed as medians and interquartile ranges, and categorical variables as percentages. Comparisons between groups were analyzed with Jonckheere-Terpstra's for ordered alternatives with pairwise comparisons, or Chi-Square test for the categorical variables. To convert the values for glucose to millimoles per liter, divide by 18. To convert the values for insulin to picomoles per liter, multiply by 6.945. To convert the values for cholesterol to millimoles per liter, multiply by 0.02586. To convert the values for triglycerides to millimoles per liter, multiply by 0.01129. <sup>a</sup>BMI 22 – 24.9 vs BMI <22; <sup>b</sup>BMI >25 vs 22 – 24.9; <sup>c</sup>BMI > 25 vs BMI < 22. Significant p-value < 0.05. 

| BMI categories (kg/m2)  |     |               |                                |                             |          |
|-------------------------|-----|---------------|--------------------------------|-----------------------------|----------|
|                         | <22 | 22-24.99      | 25-30                          | p-value                     |          |
| Sample size             | 34  | 47            | 20                             |                             |          |
| BMI, kg/m <sup>2</sup>  |     | 20.0 (2.5)    | <b>23.5</b> (1.6) <sup>a</sup> | 26.7 (2.55) <sup>b,c</sup>  | <0.0001  |
| Black race, %           |     | 6.0           | 12.0                           | 5.0                         | 0.77     |
| Waist circumference, o  | em  | 65.0 (7.0)    | 75.5 (13.2) <sup>a</sup>       | 84.0 (10.5) <sup>b,c</sup>  | <0.0001  |
| Age, yr                 |     | 42 (21)       | 39 (20.7)                      | 47 (9.5)                    | 0.24     |
| Male sex, %             |     | 33.7          | 46.5                           | 19.8                        | 0.47     |
| Glucose, mg/dL          |     | 80.0 (8.0)    | 83.0 (9.2)                     | 86.0 (11.5) <sup>b</sup>    | 0.012    |
| Insulin, μU/mL          |     | 2.5 (2.0)     | 4.3 (4.0) <sup>a</sup>         | 5.8 (6.0) <sup>b,c</sup>    | <0.0001  |
| HOMA2 % β               |     | 58.4 (37.8)   | 69.0 (45.9)                    | 84.9 (38.7) <sup>b</sup>    | < 0.0001 |
| HOMA2 %S                |     | 303.2 (261.6) | 228.2 (221.9) <sup>a</sup>     | 148.2 (75.1) <sup>b,c</sup> | <0.0001  |
| HOMA2-IR                |     | 0.3 (0.3)     | $0.4 (0.5)^{a}$                | $0.7 (0.5)^{b,c}$           | < 0.0001 |
| CRP, mg/dL              |     | 0.9 (1.5)     | 0.71 (1.2)                     | 0.6 (1.2)                   | 0.51     |
| Triglycerides, mg/dL    |     | 57.0 (27.2)   | 70.0 (29.0)                    | 123.5 (72.7) <sup>b,c</sup> | < 0.0001 |
| LDL-C, mg/dL            |     | 98.0 (30.5)   | 100.0 (34.0)                   | 101.0 (28.5)                | 0.57     |
| Total cholesterol, mg/c | IL  | 181.0 (48.7)  | 169.0 (42.0)                   | 173.0 (34.5)                | 0.13     |
| ApoA-I, mg/dL           |     | 176.0 (61.2)  | 147.0 (53.0)                   | 111.0 (57.2) <sup>b,c</sup> | <0.0001  |
| ApoB, mg/dL             |     | 73.7 (24.3)   | 81.3 (26.1)                    | 81.7 (22.3) <sup>b</sup>    | 0.04     |

# **Table 2.** Subgroup clinical characteristics according to BMI groups

| HDL-C, mg/dL | 72.5 (39.0) | 49.0 (52.0) <sup>a</sup> | 32.5 (15.0) <sup>b,c</sup> | < 0.0001 |
|--------------|-------------|--------------------------|----------------------------|----------|
| cIMT, mm     | 0.55 (0.2)  | 0.58 (0.2)               | 0.67 (0.5)                 | 0.05     |

| 698 | All continuous variables are expressed as medians and interquartile ranges, and categorical                         |
|-----|---|
| 699 | variables as percentages. Comparisons between groups were analyzed with Jonckheere-                                 |
| 700 | Terpstra's for ordered alternatives with pairwise comparisons, or Chi-Square test for the                           |
| 701 | categorical variables. To convert the values for glucose to millimoles per liter, divide by 18.                     |
| 702 | To convert the values for insulin to picomoles per liter, multiply by 6.945. To convert the                         |
| 703 | values for cholesterol to millimoles per liter, multiply by 0.02586. To convert the values for                      |
| 704 | triglycerides to millimoles per liter, multiply by 0.01129. <sup>a</sup> BMI 22 – 24.9 vs BMI <22; <sup>b</sup> BMI |
| 705 | >25 vs 22 – 24.9; <sup>c</sup> BMI > 25 vs BMI < 22. Significant p-value < 0.05.                                    |
| 706 |   |
| 707 |   |
| 708 |   |
| 709 |   |
| 710 |   |
| 711 |   |
| 712 |   |
| 713 |   |
| 714 |   |
| 715 |   |
| 716 |   |
| 717 |   |
| 718 |   |
| 719 |   |

### **Table 3**. HDL characterization

|                          | BMI categories (kg/m2) |                        |                          |         |  |
|--------------------------|------------------------|------------------------|--------------------------|---------|--|
|                          | <22                    | 22-24.99               | 25-30                    | p-value |  |
| Sample size              | 34                     | 47                     | 20                       |         |  |
| Total mass, mg/dL        | 198.8 (91)             | 182.3 (98)             | 155 (99) <sup>c</sup>    | 0.024   |  |
| Triglycerides, mg/dL     | 9.8 (6.0)              | 7.8 (4.0)              | 8.3 (6)                  | 0.047   |  |
| Free cholesterol, mg/dL  | 8.0 (6.0)              | 6.3 (4.0) <sup>a</sup> | 5.3 (3.0) <sup>c</sup>   | 0.001   |  |
| Cholesteryl ester, mg/dL | 60.1 (35)              | 52.9 (46)              | 39.7 (26) <sup>c</sup>   | 0.004   |  |
| Phospholipids, mg/dL     | 35.1 (19)              | 29.2 (14) <sup>a</sup> | 24.7 (13) <sup>c</sup>   | <0.0001 |  |
| ApoA-I, mg/dL            | 86.1 (40)              | 86.1 (48)              | 76.9 (39)                | 0.578   |  |
| Total proteins, mg/dL    | 135.5 (71.5)           | 143.6 (74)             | 147.0<br>(54.0)          | 0.777   |  |
| HDL size, nm             | 7.9 (0.9)              | 7.8 (0.9)              | 7.6 (0.8) <sup>b,c</sup> | <0.0001 |  |
| Zeta potential, mV       | -7.7 (5)               | -6.4 (4)               | -7.8 (9)                 | 0.297   |  |
| CETP, %                  | 10.1 (6.4)             | 10.6 (7.3)             | 10.7 (6.3)               | 0.612   |  |
| PLTP, µmol PC/mL/h       | 5.7 (2.9)              | 6.0 (3.2)              | 5.4 (3.5)                | 0.338   |  |
| LCAT, nmol CE/mL/h       | 17.4 (15)              | 16.6 (12)              | 16.9 (19)                | 0.454   |  |
| LPL, µmol FFA/mL/h       | 4.0 (3.4)              | 3.7 (3.7)              | 3.2 (2.9)                | 0.157   |  |
| HL, µmol FFA/mL/h        | 4.9 (4.0)              | 5.8 (4.4)              | 5.8 (4.5)                | 0.440   |  |

|     | PON/HDL-C,                                  | 0.40(0.5)                   | $0.50(0.7)^{a}$ | $0.54(0.7)^{\circ}$     | < 0.001           |
|-----|---|-----------------------------|-----------------|-------------------------|-------------------|
|     | (mmol/min)/(mg/dL)                          | 0.40 (0.3)                  | 0.30 (0.7)      | 0.34 (0.7)              |                   |
| 724 |   |                             |                 |                         |                   |
| 725 | All continuous variables are exp            | pressed as media            | ns and interqua | rtile ranges. To        | o convert values  |
| 726 | for cholesterol to millimoles per           | liter, multiply b           | у 0.02586. То с | convert values          | for triglycerides |
| 727 | to millimoles per liter, multiply           | by 0.01129. <sup>a</sup> BN | MI 22 – 24.9 vs | BMI <22; <sup>b</sup> B | MI >25 vs 22 –    |
| 728 | 24.9; <sup>c</sup> BMI > 25 vs BMI < 22. Si | gnificant p-value           | e < 0.05.       |                         |                   |
| 729 |   |                             |                 |                         |                   |
| 730 |   |                             |                 |                         |                   |
| 731 |   |                             |                 |                         |                   |
| 732 |   |                             |                 |                         |                   |
| 733 |   |                             |                 |                         |                   |
| 734 |   |                             |                 |                         |                   |
| 735 |   |                             |                 |                         |                   |
| 736 |   |                             |                 |                         |                   |
| 737 |   |                             |                 |                         |                   |
| 738 |   |                             |                 |                         |                   |
| 739 |   |                             |                 |                         |                   |
| 740 |   |                             |                 |                         |                   |
| 741 |   |                             |                 |                         |                   |
| 742 |   |                             |                 |                         |                   |
| 743 |   |                             |                 |                         |                   |
| 744 |   |                             |                 |                         |                   |
| 745 |   |                             |                 |                         |                   |
| 746 |   |                             |                 |                         |                   |
| 747 |   |                             |                 |                         |                   |
| 748 |   |                             |                 |                         |                   |
| 749 |   |                             |                 |                         |                   |

750 Table 4. Linear regression analyses between HDL functions and cIMT

| Independent variable             | Standardized β | R square | Lower<br>CI 95% | Upper CI<br>95% | <i>p</i> -value |
|----------------------------------|----------------|----------|-----------------|-----------------|-----------------|
| Antioxidant activity             | -0.196         | 0.298    | -0.003          | 0.0000.         | 0.0380.         |
| CEC                              | -0.188         | 0.249    | -0.023          | 0.000           | 0.047           |
| PON/HDL-C                        | 0.096          | 0.387    | -0.008          | 0.0760          | 0.114           |
| Anti-inflammatory<br>activity    | -0.004         | 0.264    | -0.002          | 0.0020.002      | 0.963           |
| HDL-mediated platelet inhibition | 0.109          | 0.283    | -0.002          | 0.0070.         | 0.257           |

751 Adjusted for age, sex, BMI, insulin and HDL-C. In order to compare effects across different

752 HDL functions we provided the standardized coefficients

#### Highlights

• Our study describes for the first time the multiple and complex relationship between HDL functions and excess weight in asymptomatic non-diabetic and non-obese individuals.

• BMI is inversely associated with HDL-mediated inhibition of platelet aggregation and CEC, but surprisingly it is directly associated with the antioxidant activity.

• Decreased HDL concentration, size or function are related to increased atherosclerotic burden and increased BMI.

A. B.





#### Figure 2 Click here to download high resolution image



\*Conflict of Interest Form Click here to download Conflict of Interest Form: Conflict of interest form.pdf